|

PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma

RECRUITINGSponsored by Ruijin Hospital
Actively Recruiting
SponsorRuijin Hospital
Started2024-07-23
Est. completion2029-07-23
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06755775

Summary

This study aims to investigate the predictive value of PET imaging targeting granzyme B on the outcome of patients with diffuse large B lymphoma receiving immunotherapy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Pathologic diagnosis of DLBCL
2. Patient's general condition is good and survival is expected to be greater than six months
3. Signed and dated informed consent form

Exclusion Criteria:

1. Combined with other malignant tumors
2. Patients with serious medical conditions who, in the opinion of the investigator, are not suitable for participation in this clinical study
3. Pregnant women and women at risk of pregnancy, breastfeeding women
4. poor compliant

Conditions2

CancerDiffuse Large B-Cell Lymphoma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.